Pdf Open Label Uncontrolled Multicenter Phase Ii Study To Evaluate

Study Design The Study Was A Multicenter Open Label Dose Ranging To evaluate the efficacy and safety of the epidermal growth factor receptor directed monoclonal antibody cetuximab administered as a single agent in patients with recurrent and or metastatic. Goal of this study is to determine the optimal balance between maintaining high rates of os in this group and avoiding the long term toxicity associated with therapy intensificiation.

Study Design For The Multicenter Open Label Randomized Phase Iii Patients and methods: an open label multicenter study in which patients with disease progression on two to six cycles of platinum therapy received single agent cetuximab (initial dose 400 mg m2 followed by subsequent weekly doses of 250 mg m2) for > or = 6 weeks (single agent phase). Phase ii arm 3 will assess the orr of the dual combination in metastatic braf mutant melanoma patients who are naïve to prior treatment with a selective braf inhibitor. Final analysis of a multicenter, open label, phase 2 study evaluating the efficacy and safety of tislelizumab (tis) in combination with fruquintinib (f) in patients (pts) with selected solid tumors. Open label, uncontrolled, multicenter phase ii study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum based therapy.

Pdf A Phase 1 Multicenter Open Label Dose Escalation Study Of Final analysis of a multicenter, open label, phase 2 study evaluating the efficacy and safety of tislelizumab (tis) in combination with fruquintinib (f) in patients (pts) with selected solid tumors. Open label, uncontrolled, multicenter phase ii study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum based therapy. Open label, uncontrolled, multicenter phase ii study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum based therapy. This phase ii study explored the efficacy, pharmacokinetics (pk), and safety of bth1677 combined with cetuximab carboplatin paclitaxel in untreated stage iiib iv non small cell lung cancer. Purpose: to evaluate the efficacy and safety of rc48 adc, a novel humanized anti her2 antibody conjugated with monomethyl auristatin e, in patients with her2 locally advanced or metastatic urothelial carcinoma (muc) refractory to standard therapies. This is an open label, multi center, single arm phase ii study to evaluate the efficacy and safety of t dxd for the treatment of unresectable and or metastatic solid tumors harboring specific her2 activating mutations regardless of tumor histology.